SOURCE: Cryobanks International, Inc.

March 19, 2007 08:00 ET

Cryobanks International Reports One of the Largest Inventories of Cord Blood for Transplant in the World

ALTAMONTE SPRINGS, FL -- (MARKET WIRE) -- March 19, 2007 -- True to its corporate mission statement "to become the largest provider of cord blood stem cells for transplant and research purposes in the world," Cryobanks International, Inc. (CII) continues to exhibit record growth. With over 15,000 cord blood units processed and 9,000 listed on international registries for transplant, CII continues its push to help close the gap between patient needs and available resources of donated cord blood.

Over 35,000 American children and adults with life-threatening illnesses find themselves in need of a transplant each year. That number grows to more than 150,000 annually worldwide.

According to Cryobanks' CEO, Dwight Brunoehler, as much as 80% of all the cord blood units donated and collected do not meet the rigid transplant standards. A variety of reasons including low volume, low viability, incomplete paperwork and positive bacterial fungal culturing can restrict the use of the cord blood for transplant.

In Cryobanks' case, units that are not acceptable for transplant may be used to advance research in the field. Cryobanks' policy of furnishing cord blood research units to qualified institutions is predicated on the units being used for non-controversial and non-cosmetic purposes.

About Cryobanks:

Cryobanks International is a corporation located in Altamonte Springs, FL, which is to be acquired by BioStem, Inc. (OTCBB: BTEM). The Company is a leader in the collection, processing, and banking of stem cells derived from the umbilical cord immediately after birth. The units of cord blood (CB) are processed and stored by the company for use in unrelated transplants (where the donor is a histocompatible match, but is anonymous and unrelated to the recipient) and for personal storage and use. In recent years, cord blood transplants (CBTs) have become widely recognized as a safe, effective, and in many ways preferable, alternative to bone marrow transplant (BMT). There is tremendous potential need for CBTs in the United States and worldwide. Cryobanks International is well poised to help meet that need, equipped with an inventory of over 9,000 cord blood units. For more information about Cryobanks International call 1-800-869-8608 or visit the website at

Safe Harbor Statement

This press release contains "forward-looking statements" by BioStem, Inc. These statements relate to future events or financial performance and transactions, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements, to be materially different from those contemplated by the forward-looking statements. There can be no assurance that the acquisition described herein will successfully close. We undertake no ongoing obligation, other than that imposed by law, to update these statements. Factors that could affect results, levels of activity, performance or achievements and cause them to materially differ from those contained in the forward-looking statements include the failure to complete the acquisition of Cryobanks, and other factors that can be found in BioStem's filings with the Securities and Exchange Commission, which can be found at

Contact Information